Due to a “surplus of available updated vaccines” since the pandemic, AstraZeneca announced on Tuesday that it had started the global withdrawal of its Covid-19 vaccine. Additionally, the business said that it would remove the marketing authorizations for the vaccine, Vaxzevria in Europe.
The business said that “as multiple, variant Covid-19 vaccines have since been developed there is a surplus of available updated vaccines,” this has resulted in a decrease in the market for Vaxzevria, which is no longer produced or provided.
The Anglo-Swedish pharmaceutical company reportedly acknowledged in court filings that the vaccination has adverse effects, including low blood platelet counts and blood clots.
The Telegraph, the Indian English daily newspaper, which broke the story first, stated that the company applied on March 5 to remove the vaccine, and it took effect on May 7.
Listed in London After slowing down its growth as sales of Covid-19 medications decreased, AstraZeneca started stepping into the obesity treatment market and respiratory syncytial virus (RSV) vaccines through a number of acquisitions last year.
The Oxford-AstraZeneca vaccine is made at Serum Institute of India which is situated in the Pune city and is marketed under the Covishield brand in India. Covishield is the most commonly used Covid-19 vaccine in India, with around 175 crore doses provided to date.
